Characterisation of the invasive glioma niche using Astrocyte-Glioblastoma Organoids and decellularised human brain (gliomasphere matrices)
Year: 2021
Type: dissertation
Abstract: Glioblastoma (GBM) therapeutic challenges are in considerable part due to myriad survival adaptations and mechanisms, which allow malignant cells to repurpose signalling pathways within discrete microenvironments. These Darwinian adaptations facilitate invasion into brain parenchyma and the perivascular space or promote evasion from repressive factors that represent anti-cancer defence mechanisms. While many large-scale studies and multiple innovative models have been focusing on the surgically-excised GBM tumour mass, inevitable deadly GBM recurrence usually originates from the non-resected/remaining tumour edge which is predominantly composed of astrocytes harbouring few, residual infiltrative GBM cells. This makes the GBM-infiltrated peri-tumour region more clinically-relevant to patient prognostic outcome. Furthermore, it is not yet known whether astrocytes located at the peri-tumour region can be malignantly transformed and/or can promote tumour re-population within brain parenchyma, via the effect of intercellular communications with GBM cells. We hypothesised that pre-clinical modelling of glioma invasion by recapitulating early events occurring immediately after surgery at the GBM invasive margin, could reveal the genetic cross-talk between malignant cells and the surrounding healthy astrocytes, which facilitates tumour recurrence. We firstly generated transgenic H1-derived Neural Stem Cells (NSCs) using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9-mediated knock-in of a transgene, composed of a Yellow Fluorescent Protein (YFP) reporter gene under the control of the Glial Fibrillary Acidic Protein (GFAP) promoter, at the Adeno-Associated Virus Integration Site 1 (AAVS1) safe harbour locus, to facilitate viable astrocyte isolation/re-isolation and imaging. Reproducible ultrahigh-throughput 24-AggreWell™ plates (7200 mini-wells per plate; 300 microwells in each macrowell) were used to create astrocyte-GBM cerebral organoids, which we term ‘Gliomasphere Matrices’. YFP-labelled astrocytes were co-cultured with each of 10 treatment-naïve patient-derived cell lines isolated from the GBM INvasive (GIN lines) margin based on the fluorescence of 5-AminoLevulinic Acid (5-ALA) substrate that specifically labels cells with high activation of the heme synthesis pathway, (which includes GBM cells). Co-cultures were seeded upon on a sequentially constructed, Time-of-Flight Secondary Ion Mass Spectrometry (ToF-SIMS)-characterised 3D scaffold, composed of decellularised human brain ExtraCellular Matrix (dhb-ECM) with a bio-inert PolyEthylene Glycol Diacrylate (PEGDA) hydrogel. Based on accurate spatially-controlled orientation of YFP-astrocytes within the model, two Gliomasphere Matrix phenotypes were created in line with the principles of good manufacturing practice, to provide an efficient platform for drug screening and cell-based therapy systems. YFP-astrocytes were purified from each of the 10 Gliomasphere Matrices using Fluorescent-Activated Cell Sorting (FACS) after 6- and 10-days co-culture to assess transcriptomic alterations, whereby genetic cross-talk occurred in response to direct physical contact with GIN cells. Multi-Dimensional Scaling (MDS) has shown the uniform clustering of our samples, which indicates the stringency of control on the biological conditions and technical aspects throughout the whole procedure starting from cellular differentiation, model creation, and transcriptome profiling. Additionally, gene expression changes intrinsic to tumour cells are discussed and validated in relation to RNA-sequencing data from 10 patient-derived 5ALA+ FACS-purified GBM invasive margin specimens. RNA-sequencing of the putatively reprogrammed YFP-astrocytes showed a characteristic expression of well-studied markers and molecular pathways known to be key regulators of glioma initiation and recurrence such as Notch and Akt/mTOR pathways respectively. Moreover, YFP-astrocytes upregulated an important neurodevelopmental genetic marker located at chromosome 1 (c1orf61), which has recently been shown to be associated with GBM stemness-acquirement/maintenance and epigenetic status, in addition to other cancers (especially liver cancer) in which c1orf61 was hypothesised to act as a tumour initiator and associated with metastasis. We also revealed that c1orf61 has a distinct high-expression in diffuse glioma as compared to all somatic cancers according to The Cancer Genome Atlas (TCGA) RNA-NGS data analysis. However, the normally differentiated YFP-astrocytes also overexpressed the STimulator of Interferon Genes (STING) pathway, which is an innate immune pathway known to be involved in a defence mechanism and priming resistance against tumour cells and harmful microorganisms. The simultaneous co-expression of malignant and defence ultimately suggests a fluctuating state between malignant transformation imposed by the highly infiltrative glioma cells and/or the counter-action of the normal astrocytes to these deleterious invasive cells. Furthermore, our results encourage consideration of interferon therapy at the time of glioma diagnosis to enhance/augment the STING pathway expressed by peri-tumour astrocytes, which in turn may combat the progressive process of local invasion of glioma cells. Our findings also suggest a new viral therapeutic strategy involves targeting both GBM cells and peri-tumour astrocytes, expressing the malignant neurodevelopmental marker c1orf6, that confers resistance to viral therapy. Gliomasphere Matrix is a novel multi-faceted model which offers a unique opportunity to recapitulate early molecular cross-talk which facilitates GBM recurrence. This may influence future treatment approaches and may be utilised for high-throughput drug screening.
Author: Diksin, Mohammed Asaad Mohammed
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7216642451
